



Martinez, R. S. et al. (2021) SLFN5 regulates LAT1-mediated mTOR activation in castration-resistant prostate cancer. *Cancer Research*, 81(13), pp. 3664-3678.

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.

<http://eprints.gla.ac.uk/242794/>

Deposited on: 27 October 2021

Enlighten – Research publications by members of the University of Glasgow
<http://eprints.gla.ac.uk>

SLFN5 regulates LAT1-mediated mTOR activation in castration-resistant prostate cancer

Rafael S. Martinez^{1,2,*}, Mark J. Salji^{1,2,*}, Linda Rushworth^{1,2}, Chara Ntala^{1,2}, Giovanni Rodriguez Blanco¹, Ann Hedley¹, William Clark¹, Paul Peixoto^{3,4}, Eric Hervouet^{3,4}, Elodie Renaude^{3,4}, Sonia H.Y. Kung⁵, Laura C.A. Galbraith^{1,2}, Colin Nixon¹, Sergio Lilla¹, Gillian M. MacKay¹, Ladan Fazli⁵, Luke Gaughan⁶, David Sumpton¹, Martin E. Gleave⁵, Sara Zanivan^{1,2}, Arnaud Blomme^{1,*,#}, Hing Y. Leung^{1,2,*,#}

¹ CRUK Beatson Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK.

² Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Glasgow, G61 1QH, UK.

³ Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France.

⁴ EPIGENExp, (EPIgenetics and GENE EXPression Technical Platform), Besançon France. ⁵

Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, BC V5Z 1M9, Canada; Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada.

⁶ Northern Institute for Cancer Research, The Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK.

* equal contribution

corresponding authors. Email: h.leung@beatson.gla.ac.uk, Tel: +44 141 330 3658; email: a.blomme@uliege.be, Tel: +32 4 366 24 58.

Running Title: SLFN5 regulates LAT1 in CRPC

Keywords: castration-resistant prostate cancer; proteomics; cancer metabolism; LAT1; mTOR signalling

Conflict of interest: Authors declare no competing interests.

Abstract

Androgen-deprivation therapy (ADT) is the standard of care for treatment of non-resectable prostate cancer (PCa). Despite high treatment efficiency, most patients ultimately develop lethal castration-resistant prostate cancer (CRPC). In this study, we performed a comparative proteomic analysis of three *in vivo*, androgen receptor (AR)–responsive orthograft models of matched hormone-naïve PCa and CRPC. Differential proteomic analysis revealed that distinct molecular mechanisms, including amino acid (AA) and fatty acid (FA) metabolism, are involved in the response to ADT in the different models. Despite this heterogeneity, Schlafen family member 5 (SLFN5) was identified as an AR-regulated protein in CRPC. SLFN5 expression was high in CRPC tumors and correlated with poor patient outcome. *In vivo*, *SLFN5* depletion strongly impaired tumor growth in castrated conditions. Mechanistically, SLFN5 interacted with ATF4 and regulated the expression of LAT1, an essential AA transporter. Consequently, *SLFN5* depletion in CRPC cells decreased intracellular levels of essential AA and impaired mTORC1 signalling in a LAT1-dependent manner. These results confirm that these orthograft models recapitulate the high degree of heterogeneity observed in CRPC patients and further highlight SLFN5 as a clinically relevant target for CRPC.

Significance: This study identifies SLFN5 as a novel regulator of the LAT1 amino acid transporter and an essential contributor to mTORC1 activity in castration-resistant prostate cancer.

Introduction

Androgen deprivation therapy (ADT), together with direct targeting of the androgen receptor (AR) pathway, remains the most effective treatment for patients with advanced prostate cancer (PCa). However, patients that relapse will ultimately develop a lethal form of the disease, termed castration-resistant prostate cancer (CRPC), with current second line therapeutic options providing only relatively short gain in survival. Therefore, a better understanding of the molecular mechanisms underlying treatment resistance and the identification of specific CRPC markers remain a subject of intensive research focus.

Targeting cancer metabolism, using small molecule inhibitors or diet manipulation, alone or in combination with existing drugs, represents an appealing option to further refine anti-cancer therapies (1). Due to the basal metabolism of the prostate gland, PCa is associated with distinct metabolic features, such as a reliance on oxidative phosphorylation (2) in the early stage of the disease. Progression to CRPC, as well as resistance to treatment, is often accompanied with a metabolic switch that renders PCa tumours increasingly dependent on specific metabolic pathways such as glycolysis (3), lipid and cholesterol metabolism (4). Alteration of cancer cell metabolism can result from the activation of multiple signalling pathways, which are often strongly inter-connected between each other. In prostate, AR has been shown to directly control glucose and lipid metabolism of cancer cells, thus supporting cancer progression (5) or treatment resistance (6). In addition to AR, mTORC1 signalling is frequently dysregulated in PCa (7). Regulation of cellular metabolism and protein synthesis by mTORC1 is critical to sustain the biomass required for enhanced proliferation in cancer cells. However, the limited success achieved by current mTOR inhibitors in clinics points towards the need to better characterise other factors upstream of mTOR regulation (8).

Along with growth factors, amino acid (AA) homeostasis is essential for the regulation of mTORC1 activity. Leucine, in particular, is critical for mTORC1 localisation at the surface

of lysosomes (9). Thus, an important component of this metabolic process is the L-type amino acid transporter LAT1. Mechanistically, LAT1 mediates the intracellular uptake of branched chain and aromatic AA in exchange for glutamine, in a sodium-independent manner (10). LAT1 over-expression has been reported in multiple cancer types, including PCa (11). In patients, LAT1 expression is elevated following ADT and in metastatic lesions (12,13). Mechanistically, LAT1 is regulated by the stress-induced transcription factor ATF4 and contributes to PCa progression, at least in part, by sustaining mTORC1 signalling (13).

Schlafen family member 5 (SLFN5) is a member of the Schlafen family of proteins, a group of type 1 interferon-inducible proteins. In addition to an AAA (ATPase) domain and a specific SLFN box, the *SLFN5* gene contains a helicase domain as well as a nuclear localisation sequence, which suggests a role for this protein in transcription-related processes (14). However, the molecular function of SLFN5, as well as its contribution to cancer, remains unclear. SLFN5 levels correlate with good patient outcome in melanoma (15), breast (16) and renal cancers (17), and SLFN5 expression was associated with decreased cell motility in these cell types. A recent study further reported that SLFN5 negatively regulates invasiveness and epithelial-to-mesenchymal transition in breast cancer cells by directly controlling the transcription of ZEB1 (18). By contrast, a pro-tumourigenic role for SLFN5 has been suggested in glioblastoma, where SLFN5 acts as a transcriptional co-repressor of STAT1 following type 1-interferon treatment (19). Taken together, these results suggest that the role of SLFN5 in cancer progression might be context-dependent.

In this study, we develop and characterise three *in vivo*, AR-driven, orthograft models of PCa that accurately model patient CRPC condition. In depth proteomic analysis reveals a complex response to hormone deprivation therapy, indicating distinct molecular mechanisms across the different models. Despite this molecular heterogeneity, we identify SLFN5 as a common target, the expression of which is consistently up-regulated upon ADT resistance.

SLFN5 expression is increased in treatment-resistant patient biopsies, while SLFN5 deletion dramatically impairs the growth of CRPC tumours *in vivo*. Mechanistically, we show that SLFN5 directly interacts with ATF4 and strongly controls the expression of several ATF4-

enriched target genes, including the AA transporter LAT1. Consequently, we demonstrate that SLFN5 knockout (KO) in CRPC cells alters AA metabolism and disrupts mTORC1 signalling in a LAT1-dependent manner, presenting a potential therapeutic target.

Materials and Methods

Cell culture

Hormone naïve cells (CWR22res, LNCaP and VCaP) were cultured in RPMI medium (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% foetal bovine serum (FBS, Gibco, Thermo Fisher Scientific, Waltham, MA, USA) and 2 mM glutamine (Gibco, Thermo Fisher Scientific, Waltham, MA, USA). Castration-resistant cells (22rv1 and LNCaP AI) were cultured in androgen-deprived medium consisting of phenol-free RPMI (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% charcoal stripped serum (CSS, Gibco, Thermo Fisher Scientific, Waltham, MA, USA) and 2 mM glutamine. All cells were kept in incubators set at 37°C and 5% CO₂. LNCaP (ATCC CRL-1740), 22Rv1 (ATCC CRL-2505), and VCAP (ATCC CRL-2876) were obtained from ATCC. CWR22Res cells (hormone-responsive variant of CWR22 cells) were obtained from Case Western Reserve University, Cleveland, Ohio. LNCaP AI and CWR22Rv1-AR-EK cells were obtained from Newcastle University, UK. All cell lines were authenticated by STR DNA profiling and were routinely tested for mycoplasma (every ~6 weeks) using the Mycoalert mycoplasma detection kit (Lonza, Basel, Switzerland). Cells were kept in culture for a maximum of 10 passages after recovery from frozen vials.

Generation of stable knockout and overexpressing cells

All plasmids were transfected into 10⁶ cells using Cell Line Nucleofector Kit V (Lonza, Basel, Switzerland) and the T-013 program of a Nucleofector 2b Device (Lonza, Basel, Switzerland).

22rv1 and LNCaP AI cells were transfected with commercially available *SLFN5* CRISPR/Cas9 KO Plasmid (sc-408333) and *SLFN5* HDR Plasmid (sc-408333-HDR) or control plasmids (Santa Cruz Technologies, Dallas, TX, USA). Cells were then put under

clonal selection to generate single-cell colonies. CTL and KO clones were then expanded and further selected for experiments based on SLFN5 protein expression.

For overexpressing cells, LNCaP cells were transfected with *SLFN5* (NM_144975) Human MYC-Tagged ORF Clone (RC216330, Origene, Rockville, MD, USA) or the corresponding empty vector plasmid (PS100001, Origene, Rockville, MD, USA). 22Rv1 SLFN5 KO cells were further transfected with *SLC7A5* (NM_003486) Human Tagged ORF Clone (RC207604, Origene, Rockville, MD, USA). Cells were then clonally selected, expanded and ultimately selected for further experiments based on SLFN5 or SLC7A5 protein expression.

siRNA transfection

750,000 cells were seeded in 6-well plates and allowed to attach overnight. The next day, transfections were performed using Lipofectamine RNAiMAX (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's protocol. ON-TARGETplus smartpool siRNAs against AR (L-003400-00) and ATF4 (L-005125-00), as well as non-targeting siRNA (D-001810-01-20) were purchased from Dharmacon (Dharmacon, Horizon inspired cell solutions, Cambridge, UK). AR-Vs targeting siRNA (sequence CAAGGGAGGUUACACCAAA) was a kind gift from Newcastle University. RNA or protein extraction was performed 72 hours after transfection.

Cell migration

LNCaP AI and 22rv1 cells were kept in serum-free medium for 24 hours before the experiment. Next, 500 μ l of FBS-supplemented medium were dispensed in a 24-well plate. Cells were then trypsinised and resuspended in serum-free medium at a concentration of 10^6 cells/ml (LNCaP AI) and 5×10^5 cells/ml (22rv1), and 500 μ l of the cell suspension was added

on top of 8 μ m pores inserts (Corning, New York, MA, USA). After 48 hours, the inserts were fixed in 100% methanol for 30 minutes at -20°C and subsequently stained with hematoxylin for 30 minutes at room temperature. Insert membranes were then washed with tap water and cells on the upper side were scrapped with a wet cotton bud. Finally, membranes were cut from the insert and mounted onto microscopy slides. Images were taken with a Zeiss AXIO microscope (Zeiss, Oberkochen, Germany) and further quantified using ImageJ software (v. 1.46r) or by manual counting.

Human CRPC orthografts

In vivo experiments were performed in accordance with the ARRIVE guidelines (20), and were reviewed by a local ethics committee under the Project Licence P5EE22AEE in full compliance with the UK Home Office regulations (UK Animals (Scientific Procedures) Act 1986). Prostate cancer cells were suspended in serum-free RPMI medium and mixed 1:1 with Matrigel (Corning, NY, USA). Briefly, 14×10^6 cells (in 50 μ l) were injected into the anterior prostate of CD1-nude mice (Charles River Laboratories, Wilmington, MA, USA). For CRPC conditions, orchidectomy was performed at the time of injection. Tumour growth was monitored weekly using A Vevo3100 ultrasound imaging system (Fujifilm Visualsonics, The Netherlands). Tumours were then allowed to grow for 9 weeks before reaching endpoint. At the end of the experiment, tumour orthografts were collected and weighted. Half of the tumour material was fixed in 10% formalin for histological procedures and the other half was snap-frozen in liquid nitrogen for protein, mRNA, and metabolite extractions.

Proteomic analysis of paired HN and CRPC orthografts

A detailed procedure of the proteomic analysis is given in Supplementary Methods. Briefly, 2-5 mg of tumour powder were resuspended in 150 μ l of 4% SDS containing protease

and phosphatase inhibitors. Samples were then sonicated and centrifuged at $16000 \times g$ for 10 minutes. Supernatant was collected and quantified using the BCA protein assay kit (Thermo Fisher Scientific, Waltham, MA, USA). Following protease digestion, peptides were fractionated using high pH reverse phase chromatography and further separated and analysed on an EASY-nLC II (Thermo Fisher Scientific, Waltham, MA, USA) coupled to a Linear Trap Quadrupole Orbitrap Velos mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA). MS data were processed with MaxQuant v. 1.5.2.8 and resulting proteingroups.txt output files were analysed in Perseus v. 1.5.2.4.

Transcriptomic analysis

A detailed procedure of the transcriptomic analysis is given in Supplementary Methods. Briefly, frozen tumours were manually crushed, reduced into powder and further processed using QIAshredder homogeniser columns (Qiagen, Hilden, Germany) before extraction. For cells, RNA was extracted 72 hours after initial seeding, when cells reached around 80% confluence. RNA extraction was performed using RNeasy Mini Kit (Qiagen, Hilden, Germany) with on-column DNase digestion (RNase-Free DNase Set, Qiagen, Hilden, Germany). Quality of the purified RNA was tested on an Agilent 2200 TapeStation using RNA screentape.

Libraries were prepared using Illumina TruSeq Stranded mRNA LT Kit (Illumina, San Diego, CA, USA) and run on the Illumina Next Seq 500 using the High Output 75 cycles kit (2 x 36 cycles, paired end reads, single index; Illumina, San Diego, CA, USA). FastQ files were generated using Illumina's bcl2fastq (v. 2.20.0.422). RNA-Seq paired-end reads were aligned and annotated using Tophat (v. 2.1.0). Data were analyzed and visualized using R and Bioconductor packages.

Metabolomic analysis

For a detailed procedure of the metabolomic analysis, please refer to Supplementary Methods. 10^6 cells were seeded in 6-well plates. The next day, medium was replaced and cells were allowed to grow for 48 hours. Cells were then washed 3 times with ice-cold PBS and metabolites were extracted by adding 1 ml of ice-cold extraction buffer (50% Methanol, 30% acetonitrile, 20% H_2O). Plates were incubated on a shaker at 4°C for 5 minutes and supernatant was collected, centrifuged at $16,000 \times g$ for 10 minutes and finally transferred to HPLC glass vials. Samples were kept at -80°C prior to LC-MS analysis.

MS data were acquired using a Q Exactive Orbitrap mass spectrometer (Thermo Scientific, Waltham, MA, USA) coupled with a Thermo Ultimate 3000 HPLC system according to (21). Data analysis was performed using Thermo TraceFinder v. 4.0 software.

Immunohistochemistry and analysis

All patients involved in this study gave their written informed consent. These studies were conducted in accordance with recognised ethical guidelines UBC CREB number: H09-01628 and the amendment has been reviewed by the Chair of the University of British Columbia Clinical Research Ethics Board and the accompanying documentation was found to be acceptable on ethical grounds for research involving human subjects. Biochemical relapse was defined according to the ASTRO definition and represents three consecutive rise of detectable PSA following surgery.

To assess SLFN5 protein levels, immunohistochemistry was conducted with the Ventana DISCOVERY Ultra (Ventana Medical Systems, Tucson, Arizona, USA), an automated staining platform. Formalin-fixed paraffin-embedded (FFPE) TMA sections were baked, deparaffinised, and incubated in antigen retrieval solution CC1 (Ventana) at 95°C for 64 minutes. Following, anti-SLFN5 antibody (rabbit, 1:100, ab121537, abcam,) was incubated at room temperature for 1 hour. For detection, UltraMap DAB anti-Rb Detection Kit (Ventana)

was used. Stained slides were scanned with Leica Aperio AT2 (Leica Microsystems, Concord, Ontario, Canada). The area of interest in the tumour images were delineated by pathologist. Positively stained cells were quantified with Aperio ImageScope (Leica Biosystems, Buffalo Grove, Illinois, USA).

Analysis of SLFN5 binding motifs

Analysis of putative SLFN5-binding motifs (18) in the promoter regions of *SLC7A5*, *SLC3A2*, *ATF4*, *NDNF* and *STRBP* was done with the Motif-based sequence analysis tools FIMO package (22) (MEME Suite v. 5.1.1). Promoter regions were defined as 2000bp upstream of the transcription start site using the ensemble GRCh38.93 genome assembly.

Statistical analysis

Statistical analyses were performed using GraphPad PRISM software v. 8.4.2 (GraphPad Software Inc, San Diego, CA, USA).

Antibodies and primers

A list of the antibodies used in this study is provided as Supplementary data 6. The primers used in this study are listed in Supplementary Data 7.

Data reproducibility

Figure 1: Panel D: representative image from 3 independent biological experiments.

Figure 2: Panel A: n = 1 gel loaded with three tumour orthografts per condition. Panel B: representative image from 3 tumour orthografts per condition. Panels C, F, G: representative image from 3 independent biological experiments. Panel D, H: n = 6 (3 independent biological experiments performed in duplicates). Panels E, I, K: n = 3 independent biological experiments.

Figure 3: Panels A, B: n = 151; 162; 45; 29 for untreated; NHT-treated; CRPC and NEPC respectively. Panel C: n = 38 for high SLFN5 expression and n = 47 for low SLFN5 expression. Panel D: n = 70 for Gleason score < 7 and n = 56 for Gleason score >7. Panel E: n = 153 for non-metastatic patients and n = 75 for metastatic patients.

Figure 4: Panels A, B, C, D, E: representative experiment chosen from 3 independent biological experiments. Panel C, D, E: n = 6 (3 independent fields taken from two independent migration inserts per condition). Panels F, G: representative image from 8, 9, 7 tumours for CTL, KO1 and KO2 respectively. Panels H, I: n = 8, 9, 7 tumours for CTL, KO1 and KO2 respectively. Figure 5: Panel A: representative image from 3 independent biological experiments. Panel D: n = 6 (3 independent biological experiments performed in duplicates).

Figure 6: Panels A, B, C, D, E: representative image from 3 independent biological experiments. Panel F: n = 6 (3 independent biological experiments performed in duplicates). Panel H: representative image from 2 independent biological experiments. Panel I: representative image from 3 independent biological experiments.

Figure 7: Panel A: n = 3 independent biological experiments. Panels B, C: representative image from 3 independent biological experiments. Panel D: n = 1 gel loaded with four tumour orthografts per condition.

Data availability

The raw files and the MaxQuant search results files have been deposited as partial submission to the ProteomeXchange Consortium via the PRIDE partner repository (23) with the dataset identifiers PXD021405 and PXD021428. The following databases were used in this study: The Cancer Genome Atlas (TCGA—<https://tcga-data.nci.nih.gov/tcga/>); GEPIA (<http://gepia.cancer-pku.cn/>); STRING v11.0 (<https://string-db.org/cgi/input.pl>). All the data

supporting the findings of this study are available within the article and its supplementary information files and from the corresponding author upon reasonable request.

Results

Proteomic characterisation of *in vivo* models of CRPC

To study resistance to androgen deprivation, we developed three independent PCa orthograft models to mimic clinical CRPC by injecting matched pairs (hormone naïve and castration resistant) of AR-proficient human PCa cell lines into the prostate of immunodeficient mice. In CRPC conditions, orthotopic injection was directly followed by orchidectomy to achieve ADT. LNCaP, CWR22res and VCaP were selected based on their differences in AR expression, full length and variants, and herein referred to as hormone naïve cells (HN) (Supplementary Figure 1a). HN cells were cultured *in vitro* in androgen-containing medium (supplemented with foetal bovine serum) and injected orthotopically into the prostate of uncastrated mice. By contrast, two matched, isogenic, androgen-independent (CRPC) cell lines, namely LNCaP AI and 22rv1, were routinely cultured *in vitro* in androgen-deficient medium (supplemented with charcoal-stripped serum) and orthotopically injected into castrated mice. VCaP cells, which were able to grow orthotopically in castrated mice, were injected into both uncastrated and castrated mice (Figure 1a). All models develop CRPC tumours *in vivo* and have been individually used in the literature (24). Surprisingly, the castrate models of LNCaP AI and VCaP-CR orthografts displayed a higher incidence than their HN counterparts. By contrast, CWR22res were more tumourigenic than 22rv1 (Supplementary Figure 1b). Importantly, there was no significant difference in the final tumour weight between HN and CRPC models (Supplementary Figure 1c).

Using a SILAC-based proteomic approach, we compared the proteomes of the CRPC and HN tumours within each model. This allowed us to define three independent proteomic signatures associated with CRPC (Figure 1b, Supplementary Data 1). Strikingly, enrichment pathway analysis highlighted changes in metabolism as the top pathway commonly modulated in CRPC (Figure 1c). In particular, pathways related to lipid (PPAR signalling, fatty acid

oxidation, ferroptosis) and amino acid metabolism (branched chain AA degradation) were significantly modulated upon ADT resistance (Figure 1c). However, the regulated proteins involved in these pathways varied greatly among the models, emphasising the molecular heterogeneity of CRPC (Supplementary Data 1). For instance, the 22rv1 model was characterised by enrichment in EGFR signalling. This EGFR signature was also observed to a lesser extent in the LNCaP AI model, but not in the VCaP-CR. LNCaP AI tumours were characterised by an increased expression of several components of the mitochondrial electron transport chain as well as of the unfolded protein response, while the VCaP-CR tumours displayed down-regulation of a large cluster of mitosis-associated proteins (Supplementary Data 1). This heterogeneity was further exemplified by different patterns of AR expression following ADT across the different models (decreased in 22rv1 when compared to CWR22res, increased in LNCaP AI compared to LNCaP, and strongly increased in VCaP-CR tumours in comparison to VCAP, Figure 1d). Finally, we took advantage of our proteomic approach to generate a proteomic signature characteristic of CRPC, irrespective of tumour type or AR status. We compared our proteomic datasets to identify proteins that were commonly modulated in all three models of CRPC. Interestingly, only 8 proteins were commonly regulated across the different models ($FC = 2$; $p\text{-value} < 0.05$; Figure 1b). Among these candidates, Adducin-1 (ADD1) and Schlafen Family Member 5 (SLFN5) were significantly more abundant in all CRPC tumours. Unlike ADD1, the role of SLFN5 in cancer remains understudied, which prompted us to explore its function in CRPC.

SLFN5 is an AR-regulated gene highly expressed in CRPC

We first confirmed high SLFN5 levels in CRPC orthografts by performing western blot on total tumour lysates (Figure 2a). Immunohistochemistry performed on tumour slides further evidenced a strong nuclear staining for SLFN5 in epithelial cells. In agreement with the

proteomic data, SLFN5 staining was more intense in 22rv1 and LNCaP AI tumours, when compared to their HN counterparts (Figure 2b). Increased SLFN5 expression was also observed *in vitro* following long-term androgen deprivation (Figure 2c), and was low in normal prostate epithelial cells (RWPE-1) when compared to PCa cells (Supplementary Figure 2a). AR is the main driver of ADT resistance (6) and directly regulates the expression of multiple genes involved in a plethora of biological processes that, if aberrantly regulated, are known to cause cancer pathogenesis (25). Therefore we tested the ability of AR to modulate SLFN5 expression in PCa cells. In LNCaP, short-term androgen deprivation (72 h) was sufficient to increase *SLFN5* mRNA by almost four-fold, and this effect was partially rescued by the addition of dihydrotestosterone (DHT) (Figure 2d). Furthermore, DHT treatment significantly decreased SLFN5 expression, at both mRNA and protein levels, in multiple PCa cell lines (Figure 2e-f). In general, SLFN5 expression was increased upon androgen withdrawal and showed an inverse correlation with AR expression (Figure 2g). To assess the contribution of AR to SLFN5 regulation, we first silenced AR (full length, AR-FL) using siRNA in both LNCaP and CWR22res cells. We also evaluated the ability of AR-V7 to regulate SLFN5 expression by performing specific knockdown (KD) of the AR-Vs variants in CWR22Rv1-AR-EK cells, a CRISPR-engineered PCa cell line that has lost expression of AR-FL while the expression of AR variants was maintained (26). In both cases, AR silencing significantly increased SLFN5 expression (Figure 2h-i, Supplementary Figure 2b-c). Interestingly, *SLFN5* expression was inversely correlated to the expression of the canonical AR target gene *KLK3* in PCa patients (using the PRAD TCGA dataset, Figure 2j). In another dataset of mCRPC patients (27), we further observed that high-SLFN5 expressing tumours ($EXP > 1.4$) displayed significantly low levels of AR and AR-V7 (Supplementary Figure 2d). Finally, we confirmed the binding of AR on the promoter region of *SLFN5* using chromatin immunoprecipitation (ChIP) (Figure 2k), thus validating SLFN5 as an AR target in PCa.

SLFN5 is associated with poor outcome in PCa patients

To assess the clinical relevance of SLFN5, we applied immunohistochemistry to assay for SLFN5 protein expression in a cohort of radical prostatectomy specimens. Similar to data from orthografts, SLFN5 immunoreactivity was primarily observed in the nuclei of epithelial cells (Figure 3a). SLFN5 expression was found to be highest in CRPC tumours ($n = 45$, $p < 0.0001$), followed by CRPC tumours with a neuroendocrine phenotype (NEPC, $n = 29$, $p = 0.0165$) in comparison to treatment naïve tumours ($n = 151$) (Figure 3b). Interestingly, compared to untreated tumour, SLFN5 expression was not altered following neo-adjuvant hormonal therapy (NHT-treated, median treatment time of 6 months, $n = 162$). High SLFN5 expression in patients significantly correlated with shorter relapse free survival (evaluated as time to biochemical relapse, $p = 0.004$, Figure 3c). Furthermore, SLFN5 expression was significantly elevated in high Gleason score tumours (>7 versus ≤ 7 , $p = 0.013$) (Figure 3d) and was significantly associated with increased risk of metastasis (p -value = 0.0003) (Figure 3e).

Taken together, these results suggest that SLFN5 expression is associated with progressive disease in PCa.

SLFN5 loss impairs *in vivo* growth of CRPC tumours

To evaluate the functional importance of SLFN5 in CRPC, we used CRISPR-CAS9 technology to generate SLFN5 knockout (SLFN5 KO) clones in 22rv1 and LNCaP AI cells and assessed the proliferative and migratory abilities of CRPC cells *in vitro* (Figure 4a). SLFN5 KO significantly reduced the proliferation of LNCaP AI, but not 22rv1 cells (Figure 4b). Importantly, SLFN5 loss consistently impaired cell migration in both cell types, and this effect was further observed using transient SLFN5 KD (Figure 4c-e).

Because SLFN5 was originally discovered in an *in vivo* proteomic screen, we speculated whether SLFN5 could affect the growth of CRPC tumours *in vivo*. To test this hypothesis, 22rv1 control and SLFN5 KO (CTL and KO respectively) cells were orthotopically injected into castrated mice and tumour volume was monitored weekly using ultrasonography. While SLFN5-deficient cells remained able to form solid tumours in CRPC condition (Figure 4f-g), tumour growth was strongly reduced in absence of SLFN5 (Figure 4h). In addition, partial or total tumour regression was also observed in around 25% of SLFN5 KO tumours (Figure 4i). Taken together, these results suggest that SLFN5 is important for tumour adaptation to CRPC condition, rather than for tumour initiation, and inhibiting SLFN5 may present as a potential target to regress some tumours.

SLFN5 depletion remodels the transcriptome of CRPC cells

SLFN5 has been described as a transcriptional modulator in glioblastoma (19). In agreement with a potential role in regulating transcriptional activity, SLFN5 was expressed in the nucleus of CRPC cells (Figure 5a). To understand the molecular functions of SLFN5, we compared the transcriptome of SLFN5 KO and CTL 22rv1 cells (Supplementary Data 2). Loss of SLFN5 resulted in significant alteration of 428 genes ($FC = 2$; $p\text{-value} < 0.05$), with 331 up-regulated and 97 down-regulated genes in the same direction in both KO clones when compared to CTL cells (Figure 5b). Enrichment Pathway Analysis emphasised that many transcripts altered in SLFN5 KO cells encoded for plasma membrane proteins. Cell adhesion was one of the top up-regulated pathways ($FC > 2$), while cell locomotion/migration, extracellular matrix organisation and ion transport were among the pathways that were significantly reduced in KO cells ($FC < -2$) (Figure 5c and Supplementary Data 3). We performed a similar RNAseq analysis on SLFN5-proficient and -depleted 22rv1 orthografts. Even with higher variability among *in vivo* tumour samples, we observed 88 genes that were

significantly modulated in SLFN5-deficient tumours (FC = 2, p-value < 0.05), with the majority (n = 68) of these genes being down-regulated in KO tumours (Figure 5b, Supplementary Data 2). Importantly, 22 genes were strongly down-regulated (FC < -3) in absence of SLFN5 in both the *in vitro* and *in vivo* analyses. This allowed us to define a signature of SLFN5-target genes in CRPC (Supplementary Table 1). Finally, RNAseq expression data for the top down-regulated candidates were validated by qPCR (Figure 5d).

To assess whether the transcriptional changes occurring in the absence of SLFN5 would reflect at the protein level, we further performed a proteomic comparison of the SLFN5 KO and CTL orthografts. The analysis highlighted 25 proteins that were significantly modulated (FC = 2, p-value < 0.05) in the absence of SLFN5 (Figure 5e). Among these candidates, 5 proteins (NDNF, STRBP, UBAP2, SLC7A5 and SLC3A2) belonged to the SLFN5-gene signature defined in Supplementary Table 1. Moreover *NDNF*, *STRBP*, *UBAP2* and *SLC7A5* transcript levels strongly correlated with SLFN5 expression in PCa patients (Figure 5f, PRAD TCGA dataset), thus supporting a potential transcriptional regulation by SLFN5.

Of note, SLC7A5 and SLC3A2 are the functional components of the AA transporter LAT1 which has recently gained interest as a molecular target for cancer therapies (28). We therefore sought to explore the link between SLFN5 and LAT1 in PCa.

SLFN5 controls LAT1 expression in CRPC

Down-regulation of the LAT1 (SLC7A5/SLC3A2) complex was confirmed in 22rv1-derived SLFN5 KO cells and orthografts (Figure 6a-b). Importantly, SLC7A5 expression was also decreased in LNCaP AI SLFN5 KO cells (Figure 6c) and in SLFN5-depleted PC3M cells, a metastatic PCa cell line displaying high levels of SLFN5 expression (Supplementary Figure 3a). Conversely, LAT1 expression was increased following SLFN5 overexpression in LNCaP

cells (Figure 6d). Overall, *SLC7A5* protein level was high in CRPC cell lines when compared to HN cells, and positively correlated with *SLFN5* expression (Figure 6e).

We next investigated the mechanism by which *SLFN5* regulates *LAT1* in CRPC. In a recent study, ChIPseq analysis following *SLFN5* immunoprecipitation revealed the presence of *SLFN5*-specific binding motifs in the genome of breast cancer cells (18). Interestingly, both *SLC7A5* and *SLC3A2*, as well as *NDNF* and *STRBP*, displayed enrichment of *SLFN5*-binding motifs in their promoters (Supplementary data 4). However, transient silencing of *SLFN5* by siRNA only moderately reduced *SLC7A5* expression (Figure 6f). *SLC7A5* and *SLC3A2* have also been reported as ATF4 target genes in cancer (13). In addition, negative enrichment of several ATF4-related genesets was observed in the transcriptomic analysis of the *SLFN5* KO tumours (Figure 6g and Supplementary Figure 3b), and majority of the 22 *SLFN5*-regulated genes (Figure 5b, Supplementary Table 1) were predicted to harbour strong binding sites for ATF4 (Supplementary data 5). We therefore hypothesized that *SLFN5* could act as a transcriptional modulator of ATF4 in PCa. Co-immunoprecipitation on nuclear extracts, as well as proximity ligation assay, both supported the presence of a direct interaction between *SLFN5* and ATF4 (Figure 6h-i). Moreover, enrichment of the *SLFN5*-specific motif was observed in the *ATF4* promoter (Supplementary data 4) and *SLFN5* depletion indeed reduced *ATF4* mRNA expression (Figure 6f). Silencing of ATF4 in 22rv1 cells also led to a strong decrease in *SLC7A5* mRNA expression, and this effect was amplified when *SLFN5* and ATF4 were both silenced concomitantly (Figure 6f). Finally, co-silencing of *SLFN5* and ATF4 also reduced the expression of other genes within the *SLFN5* signature, such as *KCNH5*, *NCMAP* and *NCCRPI* (Supplementary Figure 3c). Taken together, these results suggest a role for *SLFN5* in the ATF4-mediated regulation of *LAT1* in CRPC.

SLFN5 drives *LAT1*-mediated activation of mTOR in CRPC

LAT1 is a large neutral AA transporter that controls the cellular uptake of branched chain and aromatic AAs in exchange of glutamine (10). Hence, LAT1 expression is crucial for the regulation of cancer cell metabolism. To evaluate the impact of SLFN5-LAT1 depletion on the metabolism of CRPC cells, we compared the metabolic profiles of 22rv1 CTL and SLFN5 KO cells using quantitative LC-MS metabolomics. Consistent with the role of LAT1 in AA homeostasis, we observed that the levels of many AAs (Lys, Arg, Orn, Met, Leu, Ile, Tyr) were decreased in the SLFN5 KO cells (Figure 7a). By contrast, SLFN5-deficient cells also showed elevated levels of glutathione, in both reduced and oxidised forms (Figure 7a).

Changes in amino acid homeostasis are known to regulate the mTOR signalling pathway (29). Consistent with the observed changes in AA levels, SLFN5-deficient cells exhibited impaired mTOR activity, as evidenced by decreased phosphorylation levels of S6K and S6 proteins, which are two downstream targets of mTORC1 (Figure 7b). To test whether mTOR activation was dependent on LAT1, we stably re-expressed a myc-tagged version of SLC7A5 in SLFN5-deficient cells (Figure 7c). Reintroducing SLC7A5 in SLFN5 KO cells was sufficient to restore the phosphorylation levels of S6K and S6, therefore indicating that impaired mTOR signalling in SLFN5-deficient cells was due, at least in part, to the decrease in LAT1 expression. Importantly, impaired mTOR signalling was also observed *in vivo* in SLFN5 KO orthografts (Figure 7d). Finally, using the PRAD TCGA dataset we identified proteins that were significantly modulated in high vs. low SLFN5 tumours (Figure 7e). Strikingly, several down-stream effectors of the mTOR signalling pathway (p-AKT Ser473, p-S6 Ser235-236 and Ser240-244, p-4EBP1 Thr37 and p-mTOR Ser2248) were positively enriched in high SLFN5 tumours (Figure 7f). Taken together, these results suggest SLFN5 as a novel regulator of mTOR signalling in PCa.

Discussion

Overcoming resistance to AR targeted therapies remains the ultimate goal for the treatment of advanced PCa. CRPC develops in the majority of patients treated with ADT and is often associated with metastasis. The molecular heterogeneity of the CRPC disease reflects the numerous ways that tumours can evolve to escape current therapies. Indeed, point mutations (30,31), genomic deletion (32) or amplification (33) of the AR gene, reprogramming of AR signalling (34) as well as compensations from other signalling pathways (32,35) can all account for resistance to ADT (36). In this study, we characterised three different *in vivo* models that were generated to specifically study CRPC and ADT resistance. These models consist of the orthotopic injection of three pairs of isogenic, AR-responsive, human cancer cell lines into the prostate of immuno-deficient mice, before undergoing orchidectomy to achieve ADT. In depth proteomic characterisation of these three models highlighted pathways and molecular markers that are commonly involved in CRPC. Despite molecular differences between the models, that is reminiscent of the molecular heterogeneity observed in clinical CRPC samples (36), our analysis indicated that resistance to ADT was accompanied with a major rewiring of tumour metabolism, especially lipid and AA metabolism. In addition to steroid biogenesis, which plays an important role in CRPC development (37), branched chain amino acid (BCAA) and fatty acid (FA) degradation were strongly dysregulated upon resistance to ADT. BCAA catabolism serves to replenish the tricarboxylic acid cycle and is dysregulated in PCa (38), while targeting FA metabolism has been proposed as a therapeutic option in the context of CRPC and enzalutamide resistance (39,40). Ferroptosis, another lipid-related process that has recently been suggested as an important resistance mechanism against AR targeted therapies (6), was also enriched in our CRPC models. Likewise, peroxisome proliferator-activated receptor (PPAR) signalling was commonly enriched in all three models of CRPC orthografts. While AR itself remains the most influential regulator of PCa metabolism (5), the contribution of PPAR

signalling pathways to the regulation of PCa lipid metabolism has recently gained interest. For example, PPAR γ has been identified as a critical regulator of PCa invasion and metastasis (41), while PPAR α is an established AR target gene that is overexpressed in advanced PCa (42).

As well as uncovering the molecular pathways that are associated with CRPC, our analysis allowed us to define a repertoire of several candidates whose expressions were robustly associated with CRPC. Among these proteins, we focused our attention on Schlafen Family Member 5, a potential transcription co-regulator whose expression had not yet been reported in PCa. SLFN5 expression was increased in CRPC patients and was associated with poor clinical outcome. This increase in expression can be explained by the AR-dependent regulation of SLFN5 in prostate cells, an observation that was further supported by the presence of AR-binding sites in the promoter region of SLFN5 (43,44) and by the negative correlation observed between SLFN5 levels and AR, ARv7 and KLK3 expressions in prostate tumours. Furthermore, *in vitro* SLFN5 expression was reciprocally modulated following manipulation of AR function (with androgen supplements, androgen withdrawal, silencing of AR expression) in multiple PCa cell lines. However, whether the AR-dependent regulation of SLFN5 expression in CRPC tumours is directly mediated by AR or requires additional co-factors remains to be fully tested. In line with a pro-malignant role of SLFN5 in PCa, CRISPR-mediated KO of SLFN5 in CRPC cells reduced cell migration and further impaired CRPC tumour growth in castrated mice. The role of SLFN5 in cancer remains controversial. In contrast to our data, early studies in melanoma (15), breast (16) and renal cell carcinoma (17) suggested that high SLFN5 expression was correlated with favourable patient outcomes. Moreover, in these cell types, SLFN5 silencing resulted in enhanced cell migration and invasion, thus suggesting a tumour suppressive role for SLFN5. Conversely, pro-tumoural properties of SLFN5 have been described in glioblastoma (GBM), along with a transcriptomic-informed signature of SLFN5 genes in U87 glioblastoma cells (19). Surprisingly, there was

little overlap between the SLFN5 gene signature that we identified in CRPC cells and that reported for U87 cells, raising the possibility that SLFN5-mediated transcriptional activities might be cell type and/or context dependent.

By combining transcriptomics and proteomics, we identified SLC7A5 and SLC3A2, the two components of the LAT1 amino acid transporter, as targets of SLFN5 in CRPC. LAT1 is a member of the system L transporter family and mediates the intracellular uptake of BCAA and aromatic AA in exchange for glutamine (11). In PCa, LAT1 expression is associated with an increased risk of metastasis (13). LAT1 is also up-regulated following androgen deprivation (12,13) and is an independent predictor of castration resistance (12). Moreover targeting LAT-dependent AA transport has shown promising results in preclinical models (28). In CRPC cells, SLFN5 KO led to a strong downregulation of the LAT1 transporter, although the molecular mechanisms underlying this observation remain to be fully uncovered.

Based on our observation that transient SLFN5 silencing only moderately reduced SLC7A5 expression, we hypothesised that SLFN5 co-regulated SLC7A5 expression along with another transcription factor. An interesting candidate is the stress-induced factor ATF4, which has been implicated in CRPC (45). Indeed, SLC7A5 is an established target of ATF4 in PCa (13), and we have shown that SLFN5 and ATF4 were able to physically interact with each other. Moreover, the majority of the SLFN5-regulated genes (Supplementary Table 1) displayed strong ATF4-binding sites, and both ATF4 and SLC7A5 also presented SLFN5-enriched motifs in their promoter region. Finally, co-silencing of SLFN5 and ATF4 dramatically reduced the expression of the LAT1 transporter. Additional research is required to further define the molecular mechanisms connecting SLFN5 and ATF4 in the context of CRPC.

Consistent with a role for LAT1 in maintaining AA homeostasis, we observed that SLFN5 KO cells displayed low intracellular levels of essential AA, which are potent activators

of mTORC1 signalling. Leucine for example is important to maintain mTORC1 localisation at the lysosomal surface, subsequently allowing activation of the downstream signalling pathway (9). Therefore a role for LAT1 in stimulating mTORC1 signalling has been reported in the pathology of multiple diseases (11). mTOR is also frequently dysregulated in advanced prostate cancer (7) and targeting this pathway has shown promising results in preclinical models (46). However, mTOR inhibitors have shown limited efficacy in the clinic (8). One reason could be that only a subpopulation of PCa patients might benefit from such mTOR-targeted therapies. Interestingly, using publicly available data, we showed that high SLFN5 levels in patients correlate with increased phosphorylation levels of multiple down-stream effectors of the mTOR signalling pathway (p-mTOR, p-S6 and p-4EBP1). Therefore, SLFN5 expression, as well as the identification of a CRPC specific SLFN5-gene signature, could help in stratifying patients that would benefit from mTOR inhibition and may present as a potential therapeutic candidate to resensitize patients to treatment.

In conclusion, this study provides an in-depth characterisation of three PCa orthografts as preclinical models of CRPC aimed to recapitulate molecular features of ADT resistance in PCa. Our results confirm the suitability of these orthograft models to account for the high degree of heterogeneity observed in CRPC patients, and further highlight the transcriptional modulator SLFN5 as a clinically relevant target for CRPC. Mechanistically, SLFN5 controls the expression of the LAT1 transporter in CRPC cells, potentially acting through an ATF4-dependent mechanism. As a result SLFN5 deletion impairs CRPC tumour growth *in vivo*, alters CRPC cell metabolism and disrupts mTORC1 signalling in a LAT1-dependent manner. Taken together, our results support the idea of targeting metabolism for the treatment of PCa, and further establish SLFN5 as a potential target and an important metabolic regulator in CRPC.

Acknowledgements

We would like to thank the Core Services and Advanced Technologies at the Cancer Research UK Beatson Institute, with particular thanks to the Metabolomics and Proteomics Units, and the PRIDE team.

Financial Support: This work was supported by Cancer Research UK Beatson Institute core funding (C596/A17196) and CRUK core group awarded to HYL (A15151) and to SZ (A29800). This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 721746. PP and EH were funded by grants from “La ligue Contre le Cancer”, “la région Bourgogne Franche-Comté” and “Canceropole Grand Est”. RSM is a Horizon ITN Early Stage Researcher. MS is a Medical Research Council Clinical Research Fellow (MR/L017997/1). CN is the recipient of CRUK Clinical Research Fellowship (grant 300444-01).

Author contributions: RSM, MJS, AB and HYL designed the study. RSM, MJS, LR, GRB, WC, EH, ER, SHYK, LCAG, CNi, SL, LG, DS, AB performed the experiments. RSM, MJS, CN, AH, PP, EH, SL, GMM, LF, DS, AB analysed the data. RSM, PP, DS, MEG, SZ, AB and HYL interpreted and discussed the data. AB and HYL wrote the manuscript. All authors critically reviewed the manuscript.

References

1. Sanderson SM, Gao X, Dai Z, Locasale JW. Methionine metabolism in health and cancer: a nexus of diet and precision medicine. *Nat Rev Cancer* **2019**;19:625-37
2. Eidelman E, Twum-Ampofo J, Ansari J, Siddiqui MM. The Metabolic Phenotype of Prostate Cancer. *Front Oncol* **2017**;7:131
3. Zadra G, Loda M. Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities. *Cold Spring Harb Perspect Med* **2018**;8
4. Wu X, Daniels G, Lee P, Monaco ME. Lipid metabolism in prostate cancer. *Am J Clin Exp Urol* **2014**;2:111-20
5. Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, *et al.* The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. *EMBO J* **2011**;30:2719-33
6. Blomme A, Ford CA, Mui E, Patel R, Ntala C, Jamieson LE, *et al.* 2,4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer. *Nat Commun* **2020**;11:2508
7. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, *et al.* Integrative genomic profiling of human prostate cancer. *Cancer Cell* **2010**;18:11-22
8. Statz CM, Patterson SE, Mockus SM. mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review. *Target Oncol* **2017**;12:47-59
9. Sancak Y, Bar-Peled L, Zoncu R, Markhard AL, Nada S, Sabatini DM. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. *Cell* **2010**;141:290-303
10. Prasad PD, Wang H, Huang W, Kekuda R, Rajan DP, Leibach FH, *et al.* Human LAT1, a subunit of system L amino acid transporter: molecular cloning and transport function. *Biochem Biophys Res Commun* **1999**;255:283-8
11. Salisbury TB, Arthur S. The Regulation and Function of the L-Type Amino Acid Transporter 1 (LAT1) in Cancer. *Int J Mol Sci* **2018**;19
12. Xu M, Sakamoto S, Matsushima J, Kimura T, Ueda T, Mizokami A, *et al.* Up-Regulation of LAT1 during Antiandrogen Therapy Contributes to Progression in Prostate Cancer Cells. *J Urol* **2016**;195:1588-97
13. Wang Q, Bailey CG, Ng C, Tiffen J, Thoeng A, Minhas V, *et al.* Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression. *Cancer Res* **2011**;71:7525-36
14. Mavrommatis E, Fish EN, Plataniias LC. The schlafen family of proteins and their regulation by interferons. *J Interferon Cytokine Res* **2013**;33:206-10
15. Katsoulidis E, Mavrommatis E, Woodard J, Shields MA, Sassano A, Carayol N, *et al.* Role of interferon {alpha} (IFN{alpha})-inducible Schlafen-5 in regulation of anchorage-independent growth and invasion of malignant melanoma cells. *J Biol Chem* **2010**;285:40333-41
16. Wan G, Liu Y, Zhu J, Guo L, Li C, Yang Y, *et al.* SLFN5 suppresses cancer cell migration and invasion by inhibiting MT1-MMP expression via AKT/GSK-3beta/beta-catenin pathway. *Cell Signal* **2019**;59:1-12
17. Sassano A, Mavrommatis E, Arslan AD, Kroczyńska B, Beauchamp EM, Khuon S, *et al.* Human Schlafen 5 (SLFN5) Is a Regulator of Motility and Invasiveness of Renal Cell Carcinoma Cells. *Mol Cell Biol* **2015**;35:2684-98
18. Wan G, Zhu J, Gu X, Yang Y, Liu Y, Wang Z, *et al.* Human Schlafen 5 regulates reversible epithelial and mesenchymal transitions in breast cancer by suppression of ZEB1 transcription. *Br J Cancer* **2020**;123:633-43

19. Arslan AD, Sassano A, Saleiro D, Lisowski P, Kosciuczuk EM, Fischietti M, *et al.* Human SLFN5 is a transcriptional co-repressor of STAT1-mediated interferon responses and promotes the malignant phenotype in glioblastoma. *Oncogene* **2017**;36:6006-19
20. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, National Centre for the Replacement R, *et al.* Animal research: reporting in vivo experiments--the ARRIVE guidelines. *J Cereb Blood Flow Metab* **2011**;31:991-3
21. Mackay GM, Zheng L, van den Broek NJ, Gottlieb E. Analysis of Cell Metabolism Using LC-MS and Isotope Tracers. *Methods Enzymol* **2015**;561:171-96
22. Grant CE, Bailey TL, Noble WS. FIMO: scanning for occurrences of a given motif. *Bioinformatics* **2011**;27:1017-8
23. Perez-Riverol Y, Csordas A, Bai J, Bernal-Llinares M, Hewapathirana S, Kundu DJ, *et al.* The PRIDE database and related tools and resources in 2019: improving support for quantification data. *Nucleic Acids Res* **2019**;47:D442-D50
24. Cunningham D, You Z. In vitro and in vivo model systems used in prostate cancer research. *J Biol Methods* **2015**;2
25. Mills IG. Maintaining and reprogramming genomic androgen receptor activity in prostate cancer. *Nat Rev Cancer* **2014**;14:187-98
26. Kounatidou E, Nakjang S, McCracken SRC, Dehm SM, Robson CN, Jones D, *et al.* A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities. *Nucleic Acids Res* **2019**;47:5634-47
27. Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, *et al.* Genomic correlates of clinical outcome in advanced prostate cancer. *Proc Natl Acad Sci U S A* **2019**;116:11428-36
28. Wang Q, Tiffen J, Bailey CG, Lehman ML, Ritchie W, Fazli L, *et al.* Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development. *J Natl Cancer Inst* **2013**;105:1463-73
29. Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B, *et al.* Bidirectional transport of amino acids regulates mTOR and autophagy. *Cell* **2009**;136:521-34
30. Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, *et al.* A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. *Cancer Discov* **2013**;3:1020-9
31. Korpai M, Korn JM, Gao X, Rakiec DP, Ruddy DA, Doshi S, *et al.* An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). *Cancer Discov* **2013**;3:1030-43
32. Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, *et al.* Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. *Cancer Cell* **2017**;32:474-89 e6
33. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, *et al.* In vivo amplification of the androgen receptor gene and progression of human prostate cancer. *Nat Genet* **1995**;9:401-6
34. Sharma NL, Massie CE, Ramos-Montoya A, Zecchini V, Scott HE, Lamb AD, *et al.* The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. *Cancer Cell* **2013**;23:35-47
35. Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, *et al.* Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. *Cell* **2013**;155:1309-22
36. Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. *Nat Rev Cancer* **2015**;15:701-11

37. Chang KH, Li R, Kuri B, Lotan Y, Roehrborn CG, Liu J, *et al.* A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. *Cell* **2013**;154:1074-84
38. Shao Y, Ye G, Ren S, Piao HL, Zhao X, Lu X, *et al.* Metabolomics and transcriptomics profiles reveal the dysregulation of the tricarboxylic acid cycle and related mechanisms in prostate cancer. *Int J Cancer* **2018**;143:396-407
39. Schlaepfer IR, Rider L, Rodrigues LU, Gijon MA, Pac CT, Romero L, *et al.* Lipid catabolism via CPT1 as a therapeutic target for prostate cancer. *Mol Cancer Ther* **2014**;13:2361-71
40. Flaig TW, Salzmänn-Sullivan M, Su LJ, Zhang Z, Joshi M, Gijon MA, *et al.* Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade. *Oncotarget* **2017**;8:56051-65
41. Ahmad I, Mui E, Galbraith L, Patel R, Tan EH, Salji M, *et al.* Sleeping Beauty screen reveals Pparg activation in metastatic prostate cancer. *Proc Natl Acad Sci U S A* **2016**;113:8290-5
42. Collett GP, Betts AM, Johnson MI, Pulimood AB, Cook S, Neal DE, *et al.* Peroxisome proliferator-activated receptor alpha is an androgen-responsive gene in human prostate and is highly expressed in prostatic adenocarcinoma. *Clin Cancer Res* **2000**;6:3241-8
43. Barfeld SJ, Urbanucci A, Itkonen HM, Fazli L, Hicks JL, Thiede B, *et al.* c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks. *EBioMedicine* **2017**;18:83-93
44. Pomerantz MM, Li F, Takeda DY, Lenci R, Chonkar A, Chabot M, *et al.* The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. *Nat Genet* **2015**;47:1346-51
45. Pallmann N, Livgard M, Tesikova M, Zeynep Nenseth H, Akkus E, Sikkeland J, *et al.* Regulation of the unfolded protein response through ATF4 and FAM129A in prostate cancer. *Oncogene* **2019**;38:6301-18
46. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, *et al.* The translational landscape of mTOR signalling steers cancer initiation and metastasis. *Nature* **2012**;485:55-61

Figure Legends

Figure 1: Proteomic characterisation of *in vivo* CRPC orthografts. **A**, Schematic representation of the three CRPC orthograft models used in this study. **B**, Venn diagrams highlighting proteins commonly modulated (p-value < 0.05, FC = 2) in CRPC orthografts in comparison to their respective HN counterparts. Up-regulated proteins are on top; Down-regulated proteins are into brackets. **C**, Top 20 enriched pathways (KEGG pathways) significantly modulated in the proteomic analysis of CRPC orthografts. Pathway enrichment analysis was performed using the STRING database (<http://string-db.org>). **D**, Western blot analysis of AR expression in HN and matched CRPC tumour orthografts. HSC70 was used as a sample loading control.

Figure 2: *SLFN5* is an AR-regulated gene. **A**, Western blot analysis of *SLFN5* expression in HN and matched CRPC tumour orthografts. **B**, Immunohistochemical staining (top) of *SLFN5* expression in HN (CWR22res and LNCaP) and matched CRPC (22rv1 and LNCaP AI) orthografts; and representative pictures of hematoxylin/eosin staining (bottom) of the corresponding orthografts. Scale bar represents 50 μ m. **C**, Western blot analysis of *SLFN5* expression in HN and matched CRPC cell lines. **D**, RT-qPCR analysis of *SLFN5* expression in LNCaP cells treated with DHT for 48 hours in androgen-depleted (CSS) conditions. **E**, RT-qPCR analysis of *SLFN5* expression in AR⁺ PCa cells following short term DHT treatment (10 nM). **F**, Western blot analysis of *SLFN5* expression in CRPC cell lines treated with DHT for 72 hours. **G**, Western blot analysis of *SLFN5* and AR expression in LNCaP and LNCaP AI cells cultured in presence (FBS medium) or absence (CSS medium) of androgens for 72 hours. **H**, RT-qPCR analysis of *SLFN5* expression in LNCaP and CWR22res cells silenced for AR expression. **I**, RT-qPCR analysis of *SLFN5* expression in CWR22Rv1-AR-EK cells silenced for AR-Vs expression. **J**, Correlation of *SLFN5* and *KLK3* mRNA levels in the PRAD TCGA dataset (cbioportal). **K**, RT-qPCR analysis of the *SLFN5* and *KLK3* promoters after anti-AR

chromatin immunoprecipitation performed in 22rv1 cells. Panels **A, C, F, G**: HSC70 is used as a sample loading control. Panels **D, E, H**: *CASC3* was used as a normalising control. Panel **I**: *RPL13A* was used as a normalising control. Panels **D, E, H, I, K**: Data are presented as mean values \pm SD. Panel **D**: *p-value using a 1-way ANOVA with a Tukey's multiple comparisons test. Panel **E**: *p-value using a 1-way ANOVA with a Dunnett's multiple comparisons test. Panels **H, I, K**: *p-value using a two-sided Student's t-test.

Figure 3: SLFN5 expression is high in CRPC tumours and correlates with poor patient outcome.

A, Immunohistochemical staining of SLFN5 expression in treatment naïve, NHT-treated, CRPC and NEPC tumours. Scale bar represents 100 μ m. **B**, Quantification of SLFN5 expression in PCa tissue samples. **C**, Kaplan-Meier relapse-free survival analysis of prostate cancer patients stratified according to median SLFN5 expression. Time to PSA recurrence was used as biochemical parameter. **D, E**, Quantification of SLFN5 expression in PCa tissue samples according to Gleason score and metastatic status. Centre line corresponds to median of data, top and bottom of box correspond to 95th and 5th percentile, respectively. Whiskers extend to adjacent values (minimum and maximum data points not considered outliers). Panel **B**: statistical analysis was performed using a 1-way ANOVA with a Dunnett's multiple comparisons test. Panel **C**: statistical analysis was performed using a log rank test. Panels **D, E**: statistical analysis was performed using a two-tailed Mann-Whitney U test.

Figure 4: SLFN5 KO affects CRPC *in vitro* cell migration and *in vivo* tumour growth.

A, Western blot analysis of SLFN5 expression in SLFN5 KO cells. HSC70 is used as a sample loading control. **B**, Cell proliferation of SLFN5 KO (knockout) and untargeted control (CTL) cells after 24, 48 and 72 hours. Cell count is normalised to initial number of cells at the start of the experiment. **C**, Cell migration of LNCaP AI SLFN5 KO (knockout) and untargeted control (CTL) cells after 48 hours. **D**, Cell migration of 22rv1 SLFN5 KO (knockout) and untargeted control (CTL) cells after 48 hours. **E**, Cell migration of 22rv1 siSLFN5 (knockdown) and

untargeted siCTL (control) cells after 48 hours. **F**, Representative pictures of 22rv1-derived SLFN5 KO (knockout) and untargeted control (CTL) tumour orthografts. **G**, Representative pictures of hematoxylin/eosin staining of the corresponding tumour orthografts. Scale bar represents 100 μ m. **H**, Representative pictures of 22rv1 CTL or SLFN5 KO tumour orthografts monitored by ultrasound imaging (top). Quantification of tumour volume along time using ultrasonography (bottom). **I**, same as **H** but individual tumours are plotted on separate graphs. Panels **B**, **C**, **D**, **E**, **H**: Data are presented as mean values \pm SD. Panels **B**, **C**, **D**: *p-value < 0.05 using a 1-way ANOVA with a Dunnett's multiple comparisons test. Panel **E**: *p-value using a two-sided Student's t-test. Panel **H**: *p-value < 0.05 using a 2-way ANOVA with a Dunnett's multiple comparisons test.





Figure 5: SLFN5 KO remodels the transcriptome of CRPC cells. **A**, Immunofluorescence showing nuclear SLFN5 expression in LNCaP and LNCaP AI cells. Scale bar represents 10 μ m. **B**, Venn diagrams highlighting genes commonly modulated (p-value < 0.05, FC = 2) in SLFN5 KO cells (top) and tumours (bottom) when compared to their respective controls. Up-regulated genes are on top; Down-regulated genes are into brackets. **C**, Schematic representation of the down-regulated genes (p-value < 0.05, FC = 2) in SLFN5 KO cells when compared to CTL cells. Pathway enrichment analysis was performed using the STRING database (<http://string-db.org>). **D**, RT-qPCR analysis of *SLFN5* and top downregulated genes from **B** in SLFN5 KO and CTL cells. **E**, Volcano plots showing the proteins significantly modulated (p-value < 0.05, FC = 2) in the proteomic analysis of SLFN5 KO tumours. **F**, Pearson's correlation analysis of *NDNF*, *STRBP*, *UBAP2* and *SLC7A5* with *SLFN5* using the PRAD TCGA dataset. Results were obtained using the GEPIA website <http://gepia.cancer-pku.cn/>. Panel **D**: Data are presented as mean values \pm SD. Panel **D**: *p-value < 0.05 using a 1-way ANOVA with a Dunnett's multiple comparisons test. Panel **F**: statistical analysis was performed using a logrank test.

Figure 6: SLFN5 regulates LAT1 expression in CRPC. **A**, Western blot analysis of SLFN5, SLC7A5 and SLC3A2 expression in 22rv1 SLFN5 KO and CTL cells. **B**, Western blot analysis of SLFN5, SLC7A5 and SLC3A2 expression in 22rv1-derived SLFN5 KO and CTL tumour orthografts. **C**, Western blot analysis of SLFN5 and SLC7A5 expression in LNCaP AI SLFN5 KO and CTL cells. **D**, Western blot analysis of SLFN5 and SLC7A5 expression in LNCaP cells overexpressing SLFN5. **E**, Western blot analysis of SLFN5 and SLC7A5 expression in HN and matched CRPC cell lines. **F**, RT-qPCR analysis of *SLFN5*, *SLC7A5* and *ATF4* expression in 22rv1 cells silenced for SLFN5, ATF4 or both. **G**, Gene set enrichment plots analysed from SLFN5-depleted tumours transcriptomics using ATF4-related gene set obtained from Han et al, 2013. **H**, Western blot analysis of SLFN5 and ATF4 expression following anti-SLFN5 immunoprecipitation in nuclear extracts of 22rv1 cells. **I**, Proximity ligation assay of SLFN5 and ATF4 performed on 22rv1 cells. Red dots represent co-localisation. Scale bar represents 11 μ m. Panels **A**, **B**, **C**, **D**, **E**: HSC70 is used as a sample loading control. Panel **F**: Data are presented as mean values \pm SD. Panel **F**: *p-value < 0.05 using a 1-way ANOVA with a Tukey's multiple comparisons test.

Figure 7: SLFN5 expression promotes LAT1-dependent activation of mTORC1 signalling in CRPC. **A**, Steady-state levels of significantly regulated metabolites in SLFN5 KO cells when compared to CTL cells (FC > 1.2). Selected metabolites were significantly altered in at least one of the two KO cells ($p < 0.05$ using two-sided Student's t-test). **B**, Western blot analysis of SLFN5, SLC7A5, SLC3A2, p-p70S6K, p70S6K and p-S6 expression in 22rv1 SLFN5 KO and CTL cells. **C**, same analysis as **B** performed on 22rv1 SLFN5 KO and CTL cells overexpressing two different SLC7A5 constructs. **D**, Western blot analysis of p-S6 and p-4EBP1 expression in 22rv1-derived SLFN5 KO and CTL tumour orthografts. **E**, Volcano plot of the modulated proteins between high and low SLFN5 tumours using the PRAD TCGA dataset. Red and blue dots represent the proteins that are significantly up-regulated and down-

regulated (FC = 1.2, $p < 0.05$) in high SLFN5 tumours respectively. **F**, Differential expression

of p-S6 (Ser235-236 and 240-244) and p-4EBP1 (Thr37) in high and low SLFN5 tumours, according to the data generated in **E**. Centre line corresponds to median of data, top and bottom of box correspond to 90th and 10th percentile, respectively. Whiskers extend to adjacent values (minimum and maximum data points not considered outliers). Panels **B**, **C**, **D**: HSC70 is used as a sample loading control. Panel **A**: Data are presented as mean values \pm SD. Panel **F**: statistical analysis was performed using a two-tailed Mann-Whitney U test.

A**B****C****D****Figure 1**









Figure 2

A**B****C****D****E****Figure 3**




Figure 4




Figure 5




Figure 6




Figure 7